Avalon GloboCare (NASDAQ:ALBT – Get Rating) is one of 60 public companies in the "Management consulting services" industry, but how does it compare to its competitors? We will compare Avalon GloboCare to similar companies based on the strength of its valuation, risk, earnings, analyst recommendations, profitability, dividends and institutional ownership.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Avalon GloboCare and its competitors, as provided by MarketBeat.com.
Get Avalon GloboCare alerts:| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Avalon GloboCare | 0 | 0 | 0 | 0 | N/A |
| Avalon GloboCare Competitors | 54 | 447 | 962 | 15 | 2.63 |
As a group, "Management consulting services" companies have a potential upside of 46.83%. Given Avalon GloboCare's competitors higher probable upside, analysts plainly believe Avalon GloboCare has less favorable growth aspects than its competitors.
Profitability
This table compares Avalon GloboCare and its competitors' net margins, return on equity and return on assets.| Net Margins | Return on Equity | Return on Assets | |
| Avalon GloboCare | -955.48% | -460.58% | -97.43% |
| Avalon GloboCare Competitors | -56.87% | -79.82% | -7.02% |
Earnings & Valuation
This table compares Avalon GloboCare and its competitors gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Avalon GloboCare | $1.39 million | -$9.09 million | -2.57 |
| Avalon GloboCare Competitors | $1.54 billion | $108.15 million | 13.44 |
Avalon GloboCare's competitors have higher revenue and earnings than Avalon GloboCare. Avalon GloboCare is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Risk and Volatility
Avalon GloboCare has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, Avalon GloboCare's competitors have a beta of 1.76, meaning that their average stock price is 76% more volatile than the S&P 500.
Insider & Institutional Ownership
0.9% of Avalon GloboCare shares are held by institutional investors. Comparatively, 41.3% of shares of all "Management consulting services" companies are held by institutional investors. 64.0% of Avalon GloboCare shares are held by insiders. Comparatively, 29.4% of shares of all "Management consulting services" companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Avalon GloboCare competitors beat Avalon GloboCare on 9 of the 10 factors compared.
Avalon GloboCare Company Profile
(Get Rating)
Avalon GloboCare Corp. is a holding company, which engages in the development of biotechnology and the provision of healthcare services. It operates through the following segments: Real Property Operating, Medical Related Consulting Services, and Development Services & Sales of Developed Products. It offers regenerative medicine, cell-based immunotherapy, exosome technology, and rehabilitation medicine through Avalon Cell and Avalon Rehab platforms. The company was founded on July 28, 2014 and is headquartered in Freehold, NJ.
Receive News & Ratings for Avalon GloboCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalon GloboCare and related companies with MarketBeat.com's FREE daily email newsletter.